Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Navlimetostat Wet vs Dry Granulation Tablets in Healthy Females
NCT07544628Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of navlimetostat (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Plasma Concentration, Area under the concentration-time curve from time zero to time of last quantifiable concentration and 7 more. Started Apr 2026; status: recruiting.
02
Drugs
navlimetostat
Beyond the preview
Go deeper on NCT07544628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544628.